Key result
NOS3 T786C CC genotype linked to ~46% lower HDL versus TT in hypertensive patients.
Why the study?
The relationship between heredity, arterial hypertension, and dyslipidemia involving the NOS3 T786C gene promoter polymorphism remains controversial.
Does the NOS3 T786C gene promoter polymorphism affect lipid profiles in patients with arterial hypertension?
Cross-Sectional (n=116)
No
Does the NOS3 T786C gene promoter polymorphism affect lipid profiles in patients with arterial hypertension?
Effect estimate: 45.8% reduction
Absolute Event Rate: 0.58% vs 1.07%
The CC genotype of the NOS3 T786C gene promoter is associated with a more atherogenic lipid profile in patients with arterial hypertension compared to the TT genotype.
May flag CC carriers for closer lipid surveillance in hypertension; leaves open whether NOS3 genotyping informs therapy.
Objective. Polymorphism investigation of T786C gene promoter of endothelial nitric oxide synthase (eNOS/NOS3) in the arterial hypertension is a promising field for determining the relationship between heredity, hypertension, and dyslipidemia, which still remains controversial. The purpose of the study was to investigate the lipid profile, which depends on the NOS3 T786C gene promotor region polymorphism in patients with arterial hypertension. Methods. The study involved 86 patients with arterial hypertension. The control group consisted of 30 basically healthy individuals. The lipid profile in the blood serum of the studied patients was measured by commercially available kits using Biochem FC-200 analyzer (HTI, USA). The allelic polymorphism of NOS3 T786C gene promoter was studied using a polymerase chain reaction technique with electrophoretic detection of the results. Results. An increase at the level of all atherogenic fractions in the blood was found in the group of patients carrying the CC genotype compared with carriers of the TT genotype of the NOS3 gene. The total cholesterol serum level in the group of carriers of the CC genotype of NOS3 T786C gene promoter increased by 33.3% compared with carriers of the TT genotype and it was almost twice as high as the control values. In the group of carriers in the CC genotype of the NOS3 gene, the serum level of triglycerides was statistically significantly higher (2.9 times) than in the group of carriers of the TT genotype. The low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) serum levels significantly increased in patients with arterial hypertension with the CC genotype by 1.6 and 4.6 times, respectively, compared with the TT genotype carriers. The high-density lipoprotein (HDL) serum level, as an antiatherogenic factor, was statistically significantly lower (by 45.8%) in the group of the CC genotype carriers of the NOS3 gene than in the group with carriers of the TT genotype (0.58±0.06 vs. 1.07±0.03 mmol/l.) Conclusions. The increase in all atherogenic and decrease in antiatherogenic lipid parameters of the lipidogram of patients with arterial hypertension and the deepening of dyslipidemia in carriers of the CC genotype compared with carriers of the TT genotype of the NOS3 T786C gene promoter is crucial in the development of dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Підручна et al. (2024) conducted a cross-sectional in Arterial hypertension (n=116). NOS3 T786C CC genotype vs. NOS3 T786C TT genotype was evaluated on High-density lipoprotein (HDL) serum level (mmol/l) (45.8% reduction). In patients with arterial hypertension, carriers of the NOS3 T786C CC genotype had significantly higher atherogenic lipid levels and 45.8% lower HDL levels compared to TT genotype carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: